RareCyte

RareCyte is a precision biology company that develops technologies and integrated platforms for various applications, including oncology, immuno-oncology, maternal-fetal health, and cell and gene therapy. The company's flagship product is the Orion Spatial Biology platform, which enables highly multiplexed immunofluorescence staining and imaging of tissue samples. This platform combines speed and resolution, allowing comprehensive phenotypic profiling and characterization of tissue architecture, tumor heterogeneity, and immune response on whole slides within hours.

RareCyte also offers a comprehensive liquid biopsy solution, which includes the AccuCyte Sample Preparation System and CyteFinder Imaging Instrument for circulating tumor cell (CTC) and other rare cell characterization, single-cell retrieval for molecular analysis, and companion diagnostic development. The company's liquid biopsy platform has been widely adopted by academic medical centers, contract research organizations, and biopharma companies.

In addition to its product offerings, RareCyte provides Precision Biology Services, including custom assay development, research and clinical trial services for rare-cell liquid biopsy assays, and tissue-based spatial profiling. Key studies conducted by RareCyte include programs for biomarker discovery and implementation, pharmaceutical mechanism of action, and drug safety.

Key customers and partnerships

In November 2022, RareCyte was selected by Wellcome Leap to participate in the USD 50 million In Utero program, aimed at reducing global stillbirth rates. The company will utilize its rare cell platform to perform novel non-invasive characterization of the placenta, generating transcriptomic data from circulating trophoblasts to model and predict gestational development.

In January 2024, RareCyte announced a partnership with SOPHiA GENETICS, integrating the SOPHiA DDM Platform into its Precision Biology Services portfolio. This collaboration will enhance RareCyte's bioinformatics capabilities and support DNA sequencing of CTCs and cell-free DNA for cancer patient testing.

In April 2024, RareCyte partnered with to launch a new multiplex spatial biology assay service for whole-slide imaging and analysis of tissue sections. The service was enabled by RareCyte's Orion platform.